Sign up for #maw2024 updates!

IT'S #MAW2024!

It’s that time of the year again, when myopia takes centre stage in eye care.

And rightfully.
Myopia is the most significant eye health threat of the 21st Century.

Join this year’s Myopia Awareness Week, 13th – 19th May 2024, to spread the word that myopia is affecting children worldwide, but we have the treatments to slow its progression.

#MAW2024 resources

Access campaign and ECP practitioner resources to take action and help slow the growing prevalence of myopia!

The ECP toolkit contains a range of promotional resources to show your support online and spread the word about #myopiaawarenessweek.

A range of ECP Practitioner resources from leading organisations and groups in myopia management have been collated for use in your practice to help educate, treat and manage myopia in patients.

Remember to use the hashtags #MyopiaAwarenessWeek and #MAW2024, and tag BHVI & RMM’s accounts!

Brien Holden Vision Institute (BHVI) is not-for-profit research & development organisation working in the ophthalmic space. BHVI invents, prototypes and licenses innovative contact lens designs and intraocular lenses.

In the myopia space, BHVI’s designs are at the forefront of worldwide ophthalmic industry efforts to slow the progression of near-sightedness in children, a condition that is sharply rising in prevalence worldwide.

learn more about bhvi

Review of Myopia Management is a leading online publication designed to help eye care professionals maximize the emerging field of myopia management. Jobson Optical Group launched Review of Myopia Management (RMM) in March 2019 as the first multi-platform digital asset dedicated to myopia management. Since its inception, RMM has remained committed to producing and sharing the most up-to-date information and educational tools for eye care professionals. The online publication has grown to be the leading source of clinical, practice management, and research information on myopia management.

visit reviewofmm.com

About bhvi

Brien Holden Vision Institute (BHVI) is not-for-profit research & development organisation working in the ophthalmic space. BHVI invents, prototypes and licenses innovative contact lens designs and intraocular lenses.

In the myopia space, BHVI’s designs are at the forefront of worldwide ophthalmic industry efforts to slow the progression of near-sightedness in children, a condition that is sharply rising in prevalence worldwide.

About review of myopia management

Review of Myopia Management is a leading online publication designed to help eye care professionals maximize the emerging field of myopia management. Jobson Optical Group launched Review of Myopia Management (RMM) in March 2019 as the first multi-platform digital asset dedicated to myopia management. Since its inception, RMM has remained committed to producing and sharing the most up-to-date information and educational tools for eye care professionals. The online publication has grown to be the leading source of clinical, practice management, and research information on myopia management.

#myopiaawarenessweek
a proud initiative between

BHVI & Review of Myopia Management

About BHVI

Brien Holden Vision Institute (BHVI) is not-for-profit research & development organisation working in the ophthalmic space. It is a company limited by guarantee, incorporated in Australia. It is regulated by the Australian Charities and Not-for-profits Commission (ACNC).

The Charity Programs (ACNC)

  • Ophthalmic R&D in myopia, presbyopia, astigmatism (Diseases & Conditions).
  • Optometry Education & Knowledge (Higher Education).
  • Clinical and metrology services to support R & D technology development (Diseases & Conditions).

The assets and income of BHVI are applied solely towards the promotion and furtherance of the objects of the Company as set out in its constitution.

Copyright © Brien Holden Vision Institute (ABN 49 081 303 282). All Rights Reserved.

Our site uses cookies. By continuing to use this website, you agree to their use. For more details, please check our Privacy Policy.